Oncology Analytics, an Atlanta, GA-based provider of solutions purpose-built for oncology, closed a Series C funding round of $28M.
The round was led by Baird Capital with participation from existing investors Oak HC/FT, McKesson Ventures, and The Blue Venture Fund.
The company intends to use the funds to expand its oncology-focused capabilities, accelerate real-world data and analytics solutions for health plans, and increase the market share of its technology-enabled utilization management solution. In conjunction with the funding, Michael Liang, partner at Baird Capital, joined Oncology Analytics’ Board of Directors.
Led by Rick Dean, CEO, Oncology Analytics is a data analytics and technology-enabled services company dedicated to helping health plans, providers, and patients with solutions that are purpose-built for oncology. Through an evidence-based, real-world analytics approach to utilization management, the company’s prior authorization platform is used by physicians to support 5 million health plan members in the US and Puerto Rico and covers the full spectrum of therapeutics, across all cancer types and stages, including chemotherapy, radiation therapy, precision medicine, targeted therapy, and supportive care.